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A Practical and Pathophysiologic Approach to Hypokalemia
Shih-Hua Lin
Hypokalemia is not an isolated disease but an associated finding in a vast number of different diseases; it poses
a great challenge in correct diagnosis and proper management. Hypokalemia usually arises from a shift of
potassium (K+) into cells and/or a net loss of K+. Besides a detailed history and physical examination,
measurement of K+ excretion rate with freshly-voided and/or 24-hour urine and assessment of blood acid-base
status can help discriminate between the various causes of hypokalemia. In patients with a low rate of K+
excretion, hypokalemia can be due to an acute shift of K+ into cells, intestinal/sweating K+ loss, or prior renal
K+ excretion. In patients with a high rate of K+ excretion, there may be either increased flow rate or increased
K+ secretion, seen with fast sodium (Na+) or slow chloride (Cl–) disorders, in the cortical collecting ducts
(CCD). An increased flow rate in the CCD arises from increased osmole excretion (whether solutes or
electrolytes). Patients with fast Na+ disorders have a high extracellular fluid (ECF) volume and thus high blood
pressure associated with a state of high mineralocorticoid activity. Measurement of renin activity, aldosterone,
and cortisol levels in plasma helps distinguish between the causes. Patients with slow Cl– disorders usually
have low to normal ECF volume and blood pressure and are usually associated with abnormal acid-base states.
In patients with metabolic alkalosis, urine Na+ and Cl– excretion rate reveal the basis for renal Na+ wasting and
distinguish it from non-renal Na+ loss. In patients with hyperchloremic metabolic acidosis, an assessment of
the ammonium excretion rate (NH4
+) separates those with renal tubular acidosis (low NH4
+ excretion) from
those with other causes. The treatment of hypokalemia depends on the degree and timing of hypokalemia,
clinical manifestations, underlying causes, and potential risks from associated conditions. [Hong Kong J Nephrol
2008;10(1):14–26]
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INTRODUCTION
Potassium (K+), a major intracellular cation, functions
in critically maintaining the osmotic equilibrium of the
cell and the electrical gradient across the cell membrane.
Most of the cellular K+ in the body (~50 mmol/kg, 98%)
resides primarily in the skeletal muscles (3,000 mmol),
red blood cells (300 mmol), and liver (200 mmol). In
contrast, the total K+ content in the extracellular fluid
(ECF) is very low (< 1 mmol/kg, approximately 2%)
and similar to the daily dietary K+ intake and renal
excretion of K+. Plasma K+ concentration represents a
function of total body K+ and the distribution between
intracellular fluid (ICF) and ECF stores. Hypokalemia
usually arises from redistribution of K+ from ECF to
ICF stores and/or a consequence of total body K+
depletion. The most significant effects of hypokalemia
are on the cardiovascular, neuromuscular, renal and
metabolic functions (Table 1) [1–6]. In addition,
hypokalemia is also associated with increased mortality,
likely due to the profound effects on arrhythmogenesis,
blood pressure, and cardiovascular morbidity.
Hypokalemia is the most common electrolyte
abnormality encountered in clinical practice. One
should understand that hypokalemia per se is not a
specific disease but an associated finding in a large
number of different diseases. The rapid identification
of its underlying causes with appropriate management
is still challenging. Although several articles about
hypokalemia have been extensively reviewed [7–12],
I discuss a more practical and pathophysiologic
approach to hypokalemia and introduce some important
concepts in managing hypokalemia in this review.
K+ HOMEOSTASIS
K+ concentration in the ICF is close to 35-fold greater
than that in the ECF. Renal excretion in response to a
K+ load is relatively slow (approximately 50% within
the first 4 hours). To avoid retained K+ in the ECF and
the ensuing hyperkalemia, there must be sensitive
regulatory mechanisms to dampen plasma K+
concentration before complete renal K+ excretion. The
mechanisms regulating the distribution of K+ between
the ICF and ECF are known as the internal K+ balance
in contrast to the external balance of renal K+ excretion.
Derangements in either the internal balance (e.g. K+
shift) or external balance (e.g. K+ wasting) can result
in hypokalemia [13,14].
Regulation of K+ between ICF and ECF
The movement of K+ ions across cell membranes has
two requirements: (1) a driving force; (2) a K+ ion
channel in that membrane (Figure 1).
Driving force: The force driving K+ shift into cells
is the more negative voltage in cells. This is created by
Na-K-ATPase. Na-K-ATPase extrudes three sodium
ions (Na+) for every two K+ ions that enter cells, thus
producing a net export of positively charged ions [15].
Table 1. Clinical signs and symptoms of hypokalemia
Cardiovascular
● ECG changes: flattened or inverted T waves, prominent U wave, depressed, prolonged QT interval
● Arrhythmias: atrial tachycardia with or without block, premature ventricular contraction, ventricular tachycardia and/or fibrillation,
torsades de pointes, atrioventricular block or dissociation
● Hypertension
Neurologic/neuromuscular
● Neurologic: paresthesia, decreased deep tendon reflexes
● Skeletal muscle: cramp, myalgia, rhabdomyolysis, weakness, paralysis
● Gastrointestinal tract: reduced gastrointestinal motility (nausea, vomiting, constipation, paralytic ileus)
● Genitourinary tract: hypomotility with dilatation of bladder (hypotonic bladder)
Renal
● Metabolic alkalosis due to increased HCO
3
– reabsorption and ammoniagenesis in the proximal tubule, decreased urinary citrate excretion,
increased H+ secretion in the cortical collecting duct
● Impaired medullar concentration
● Renal cystic disease, interstitial scarring, and renal insufficiency
● Increased renal stone formation
Metabolic
● Decreased insulin release with hyperglycemia
● Impaired end-organ sensitivity to insulin with carbohydrate intolerance
● Inhibited aldosterone secretion, but stimulated renin secretion
● Worsened hepatic encephalopathy
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Because impermeable ICF anions (macromolecular
phosphates such as RNA, DNA, phospholipids) cannot
follow the Na+ movement, a negative intracellular
voltage is generated. The main hormones that increase
the activity of Na-K-ATPase include `
2
-adrenergic
agonists, insulin and thyroid hormone [15,16]. Increases
in the concentration of Na+ inside cells can also activate
Na-K-ATPase. For instance, insulin stimulates a
membrane Na+/H+ exchanger (NHE) [17], thus helping
prevent hyperkalemia when K+ is ingested in
carbohydrate-rich food. Metabolic alkalosis also affects
the NHE and causes K+ shift into cells.
K+ channels: K+ channels are a diverse and
ubiquitous family of membrane-spanning proteins that
selectively conduct K+ ions across the cell membrane
along its electrochemical gradient in both excitable and
non-excitable cells [18]. There are several different
types of K+ channels. These K+ channels share the
common features of a water-filled permeation pore
allowing K+ ions to flow across the cell membrane, a
selectivity filter that specifies K+ as the permeant ion
species, and a gating mechanism that serves to switch
between open and closed channel conformations [19].
Some of these channels are regulated by voltage, others
by ligands such as calcium ions (Ca2+) and metabolites
such as adenosine triphosphate (ATP). Because K+ ions
do not reach diffusion equilibrium, control of the open-
probability of K+ channel regulates the transmembrane
voltage. K+ channels are inhibited by barium and other
drugs [20]. Closure or opening of them may not only
alter the membrane potential but also acutely affect the
plasma K+ concentration.
Renal handling of K+
K+ is freely filtered in the glomerulus. Most of the
filtered K+ is reabsorbed by the proximal tubule and
the loop of Henle. The final amount of K+ excreted in
the urine is primarily controlled by the late distal
convoluted tubule, the connecting tubule, and the
cortical collecting duct (CCD) [14,21]. Two factors
influence the rate of excretion of K+: the flow rate in
the terminal CCD and the net secretion of K+ by
principal cells in the CCD which raises the luminal
concentration of K+ ([K+]
CCD
) (Figure 2). There is an
interplay between the magnitudes of the flow rate in
the CCD and the [K+]
CCD
 that permits the kidney to
excrete all the K+ that is ingested in steady state [22].
The flow rate in the CCD: The flow rate in the CCD
is directly proportional to the rate of excretion of
osmoles and can be expressed as the urine osmole
excretion rate divided by plasma osmolality (Uosm ×
volume/plasma osm) because urine osmolality in the
terminal CCD is equal to the plasma osmolality when
antidiuretic hormone (ADH) is present [23]. While the
rate of flow in the CCD is high during a water diuresis,
the rate of K+ excretion need not be elevated, even with
mineralocorticoid effects, because ADH must be
present to have high rates of K+ secretion [24]. Using
spot urine, the flow rate in the CCD can be indirectly
represented by Uosm/Ucreatinine (see below).
Figure 1. K+ homeostasis: the internal balance of K+. The circle
depicts the cell membrane. Na+/K+-ATPase, NHE, and K+ channels
are three major elements controlling K+ shift. The Na+/K+-ATPase
pumping Na+ out of cells in exchange for two K+ entering cells
causes a large internal negative voltage and is activated by `
2
-
adrenergics, insulin and thyroid hormone. Also, insulin, by
activating NHE, causes the electroneutral entry of Na+ into cells,
and thereby the net exit of positive voltage via the Na+-K+-ATPase.
K+ exiting cells through K+ channels is responsible for generating
the majority of the resting membrane potential.
Figure 2. Fast Na+ and slow Cl– in CCD. The barrel-shaped
structures represent the terminal CCD. The reabsorption of Na+
faster than Cl– (right panel) or Cl– slower than Na+ (left) in the
CCD creates the lumen negative voltage that drives the net secretion
of K+. Fast Na+ disorders cause ECF volume expansion and high
blood pressure whereas slow Cl– disorders lead to diminished ECF
volume and low to normal blood pressure.
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[K+]
CCD
: K+ secretion in the CCD depends on the K+
channel conductance of the apical membrane (primarily
renal outer-medullary K [ROMK]) driven by the
electrogenic reabsorption of Na+ (a lumen-negative
transepithelial voltage) via epithelial Na+ channels
(ENaC) [10,14]. Blood aldosterone and luminal
bicarbonate are two major factors enhancing K+
secretion in the CCD [22,25]. Aldosterone action leads
to an increase in the activity of ENaC by activating
various serum and glucocorticoid-regulated kinases
(SGK) which phosphorylate the ubiquitin ligase Nedd-
4-2 and reduce its interaction with ENaC as well as
channel-activating proteases (CAP 1-3) which activate
ENaC by increasing its open-probability [26]. The
concentration of HCO
3
– and/or an alkaline luminal pH
appear to exert a decrease in the apparent permeability
of Cl– and/or an increase in ROMK open probability in
the CCD, although the mechanism has not been fully
validated. There are two ways to generate more
negativity in the lumen of the CCD and thus drive K+
secretion via the ROMK channel. When Na+ is
reabsorbed faster than Cl– (fast Na+ disorders) or Cl– is
reabsorbed slower than Na+ (fast Na+ disorders), the
lumen of the CCD becomes more negatively charged
(electrogenic) and drives K+ secretion via the ROMK
channel [24]. The [K+] in the CCD can be estimated by
calculating the transtubular potassium gradient (TTKG)
as {(urine/plasma [K+])/(urine/plasma osmolality)} [27,
28]. The TTKG is a semiquantitative index that reflects
the driving force of K+ secretion in the CCD because it
adjusts for plasma K+ concentration and for water
reabsorption in the medullary collecting ducts [27]. A
TTKG that is greater than 3 in the presence of
hypokalemia indicates fast Na+ or slow Cl– disorders
(electrogenic), whereas a TTKG that is less than 3
indicates that Na+ is not reabsorbed faster than Cl–
(electroneutral) as seen with extrarenal or former renal
K+ loss. Of note, TTKG cannot be calculated if the urine
osmolality is appreciably less than the plasma
osmolality.
Opening of K+ channels are crucial for K+ secretion
in the CCD. Although many types of K+ channels have
been identified in renal tubules, the ROMK channel
(Kir 1.1; secretory K+, small K+, or SK channel) (a low-
conductance 35 pS) and large-conductance (140 pS),
Ca2+-activated K+ channels (BK, maxi-K+ channels) are
two particularly important channels [29,30]. Opening
of ROMK is primarily driven by a lumen-negative
transepithelial voltage. Maxi-K+ channels are stimulated
as a result of increased intracellular Ca2+ when flow
rate to the CCD is increased. The importance of maxi-
K+ channels in renal K+ secretion is further supported
by the finding that patients with Bartter’s syndrome,
due to inactivation mutations of ROMK in the ascending
limb of Henle’s loop and distal tubules, do not have
hyperkalemia but hypokalemia [31]. Mutations of
ROMK decrease NaCl and flow reabsorption in the
thick ascending limb, resulting in increased distal
delivery of NaCl and fluid to the CCD which increases
flow-stimulated K+ secretion via maxi-K+ channels
despite the loss of functional ROMK in the CCD [32].
ASSESSMENT OF URINE K+ EXCRETION RATE
A major branch point in hypokalemic pathophysiology
is the renal K+ excretion response during hypokalemia.
The 24-hour urine and/or spot urine have been used to
assess renal K+ excretion rate. However, 24-hour urine
collection can be cumbersome to the patient and is
frequently erroneous because of inaccurate timing,
collection and calculation. More importantly, it is
implausible to collect urine for 24 hours during
emergency situations and in states of acute K+ shift into
cells. Furthermore, KCl, volume expansion, or drugs
affecting K+ excretion (e.g. diuretics) may interfere with
the validity of the 24-hour urinary K+ collection. We
prefer a spot (timed) urine collection prior to therapy
as a fast and practical alternative. Nevertheless, 24-hour
urine, if collected properly, can provide additional
information such as how much K+ is needed to replace
a K+ deficit and the state of K+ balance from calculation
of K+ input and output. Five spot urine indices of renal
response to hypokalemia have been used: urine K+
concentration, fractional excretion of K+, TTKG, K+/
Cr ratio and Uosm/Cr (Table 2) [33–38].
Table 2. Tests used to assess the K+ excretion rate for hypokalemia
Test Unit Expected Pitfalls
24-hr urine mmol/d < 15 Inaccurate or incomplete collections, K+ shift, drugs
Spot urine
Random urine [K+] mmol/L None Polyuria or oligouria
Fractional excretion of K+ % < 3% Need nomogram if renal function impairment
K+ to creatinine ratio mmol/mmol < 1.5 Renal failure, muscle mass, volume depletion, severe rhabdomyolysis
TTKG < 3 Low urine osmolality
Osmolality to creatinine ratio mosm/mmol 120–150 As in K+/Cr ratio
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CAUSES OF HYPOKALEMIA
Based on the urinary K+ excretion rate in response to
hypokalemia, the etiology of hypokalemia can be
simply divided into two groups: those with a low K+
excretion rate and those with a high K+ excretion rate.
Disorders with a low urine K+ excretion rate
Low urine K+ excretion can be caused by an increased
transcellular shift of K+ or excessive loss of K+ from
the intestinal tract or sweat glands. In contrast to either
metabolic acidosis or alkalosis commonly found in
gastrointestinal or sweat K+ loss as a result of a
concomitant bicarbonate (HCO
3
–) or chloride (Cl–) loss,
an acid-base imbalance is usually not prominent in
patients with increased intracellular shift of K+ [35,39].
This is because ECF K+ content is relatively small and
every K+ entering cells is exchanged for H+ or Na+ out
of cells to maintain electroneutrality. However, the
amount of H+ that enters the ECF compartment and is
buffered by HCO
3
– is minute compared to the ECF
HCO
3
– content. Accordingly, the simultaneous
assessments of blood acid-base state also helps
discriminate the causes of hypokalemia with low urine
K+ excretion rate (Figure 3).
As a whole, increased shift of extracellular K+ into
cells can occur acutely in a number of highly stressful
conditions associated with increased catecholamines
or hyperinsulinemia via the activation of membrane
Na-K-ATPase or NHE activity [40,41]. Barium
intoxication and chloroquine overdose cause
hypokalemia via the direct closure of cellular
membrane K+ channels [42,43]. We would like to
clarify the clinical definition of hypokalemic periodic
paralysis (HPP) which has been used with confusion
in many causes of hypokalemia with paralysis. HPP
is specifically used for any hypokalemic disorders
caused by an acute shift of K+ into cells in contrast to
non-HPP where there is a large total body deficit of
K+ [44]. Within the HPP subgroups, the most common
are thyrotoxic periodic paralysis (TPP) in Asia [45,
46] and familial periodic paralysis (FPP) due to gene
mutations encoding the dihydropyridine-sensitive
voltage-gated Ca2+ channel _1-subunit (CACNA1S)
and tetradoxin-sensitive voltage-gated Na+ channel
_-subunit (SCN4A) of skeletal muscle in Western
countries [47,48].
Any cause of gastrointestinal K+ loss and excessive
sweating can lead to hypokalemia with low urinary K+
excretion. Of note, metabolic alkalosis and/or acidosis
is usually present as mentioned above. Furthermore,
other electrolyte excretion rates, such as Na+, Cl–,
divalent ions, and osmoles, are frequently low prior to
therapy [35]. However, sometimes, patients with
gastrointestinal or sweat loss may have high urine K+
excretion because concomitant Na+ loss with secondary
hyperaldosteronism, metabolic alkalosis with
bicarbonaturia, hypomagnesemia, and coexisting
intrinsic renal disorders all contribute to renal K+
wasting [49,50].
Disorders with a high urine K+ excretion rate
Hypokalemia due to renal K+ wasting is chronic and
usually related to disorders with either increased flow
rate to the CCD or increased K+ in the CCD (fast Na+
or slow Cl–).
Figure 3. Algorithm for the
approach to hypokalemia with
a low urine K+ excretion.
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Increased urine flow rate to CCD
Flow rate to the CCD is enhanced when osmole
excretion rate is increased. Increased osmole excretion
rate can be caused by increased excretion of electrolytes
(diuretics or tubular defects) or non-electrolytes
(mannitol, glucose, urea) [27,28] (Figure 4).
Increased [K+] in the CCD
Fast Na+ disorders: Because Na+ reabsorption in the
CCD is augmented, ECF volume is usually expanded
and thus blood pressure is high, as in states of
mineralocorticoid excess [51]. In this setting,
measurement of plasma renin activity, aldosterone and
cortisol concentration helps narrow the differential
diagnosis of fast Na+ disorders [12,28,52] (Figure 4).
Plasma renin activity and aldosterone levels are high
in patients with a renin-secreting tumor, renal vascular
s t e n o s i s ,  m a l i g n a n t  h y p e r t e n s i o n ,  a n d
pheochromocytoma. High plasma aldosterone levels but
low plasma renin activity indicates primary
hyperaldosteronism which can be caused by bilateral
adrenal hyperplasia, adrenal adenoma/carcinoma,
glucocorticoid-remediable aldosteronism or others [53].
In contrast, low plasma aldosterone level and renin
activity represents pseudohyperaldosteronism [54].
Based on the plasma cortisol concentration, three
subgroups can be readily divided. Patients with high
plasma cortisol concentrations may have ectopic
adrenocorticotropic hormone, Cushing’s syndrome or
exogenous hydrocortisone administration [55,56]. Low
plasma cortisol concentration suggests the diagnosis
of congenital adrenal hyperplasia due to either 17_-
hydrolyase or 11`-hydroxylase deficiency [57]. A
normal plasma cortisol level has been found in the
following causes: 11-deoxycorticosterone (DOC)
producing adenoma, autosomal dominant Liddle’s
syndrome due to a gain of function mutation in the
C-terminal part of the ` or a subunit of ENaC, and
failure of the 11`-hydroxysteroid dehydrogenase-2
(11`-HSDH-2) to remove cortisol resulting in apparent
mineralocorticoid excess from either a hereditary defect
due to a homozygous deficiency of 11`-HSDH-2 or
licorice ingestion (inhibition) [51,58–60].
Because aldosterone synthesis and secretion can be
inhibited by hypokalemia itself, the effect of
hypokalemia should be taken into consideration when
interpreting plasma aldosterone concentration [61]. One
must also be concerned about the effect  of
antihypertensive drugs such as angiotensin-converting
enzyme inhibitors (ACEIs), angiotensin II (AII)
antagonists, and beta-blockers which may influence
plasma renin activity and aldosterone concentrations.
Diuretics (thiazides or loop diuretics) prescribed to
hypertensive patients can cause or aggravate
hypokalemia and metabolic alkalosis while mimicking
the clinical and laboratory finding of mineralocorticoid
excess. To differentiate a diuretic-induced hypokalemia
from a true mineralocorticoid excess state, withdrawal
of diuretics coupled with replacement of the K+ deficit
can be employed. Once plasma K+ level is normal, stop
K+ supplementation. If hypokalemia recurs, excess
mineralocorticoid state is more likely than a diuretic-
induced hypokalemia.
Slow Cl– disorders: Because Cl– reabsorption in the
CCD is diminished, ECF volume is usually contracted
and thus blood pressure is relatively low to normal.
Because intracellular K+ loss is often accompanied by
ECF HCO
3
– or Cl– loss, slow Cl– disorders can have
either hyperchloremic metabolic acidosis or
hypochloremic metabolic alkalosis (Figure 4).
H y p e rc h l o r e m i c  m e t a b o l i c  a c i d o s i s :
Hyperchloremic metabolic acidosis provides an
important diagnostic clue for the presence of a
pathophysiologic process involving both K+ depletion
and direct or indirect loss of HCO
3
–. Estimating the
urine NH
4
+ concentration unveils the basis of metabolic
acidosis associated with K+ depletion [62]. The
excretion of NH
4
+ is low in patients with renal tubular
acidosis (RTA), whereas this excretion is not depressed
in simple gastrointestinal loss of NaHCO
3
 [63]. Because
direct measurement of urine NH
4
+ concentration is
usually unavailable in most laboratories, an indirect
estimate of NH
4
+ can be obtained from the urine anion
gap (Na+ + K+ – Cl–) or osmolar gap (measured –
calculated urine osmolality/2). Positive urine net charge
and osmolar gap < 100 mosm/kgH
2
O are indicative of
low urine NH
4
+ excretion, pointing to the diagnosis of
RTA [64]. RTA can be proximal or distal in origin.
Intravenous NaHCO
3
 loading at a rate of 2–3 mmol/
kg/hr can be administered to separate proximal from
distal RTA. Fractional excretion of bicarbonate
(FE
HCO3–
) as an index of proximal tubule H+ secretion
at plasma bicarbonate close to 24 mmol/L is > 15% in
proximal RTA, whereas urine-blood carbon dioxide
gradient (6U-B P
CO2
), an index of distal renal tubule
H+ secretion in the alkaline urine (pH > 7.4) is less than
25 mmHg in distal RTA [65]. The causes for patients
who do not have a low NH
4
+ excretion rate include
gastrointestinal loss of HCO
3
–, chronic toluene abuse,
treatment of diabetic acidosis with insulin, and ureteral
diversion [66,67].
Hypochloremic metabolic alkalosis: Metabolic
alkalosis is diagnostically useful in patients with severe
KCl depletion. An assessment of urine Na+ and Cl– may
reveal the basis for renal tubular electrolyte disorders
and distinguish it from non-renal Na+ loss. Low
excretion of Na+ and Cl– indicate remote vomiting,
remote or yesterday’s diuretics, Cl–-losing diarrhea (e.g.
congenital chloridorrhea), or excessive sweating [68].
Low urine Na+ but high Cl– excretion in the presence
of hypokalemia and metabolic alkalosis suggests
laxative abuse or some chronic diarrhea states with
Hong Kong J Nephrol • April 2008 • Vol 10 • No 1 21
Practical and pathophysiologic approach to hypokalemia
chronic stimulation of renal NH
4
+ excretion. Conditions
of high Na+ excretion but low Cl– suggests the presence
of an anion that is not reabsorbed. If the urine is alkaline
(pH > 7), vomiting and/or ingestion of bases is the likely
cause. If the urine is not alkaline, intake or generation
of anions that are poorly reabsorbed by the kidney is
likely [69]. A high urine Na+ and Cl– excretion in the
presence of ECF volume depletion is indicative of the
recent use of diuretics, intrinsic renal disease or the
lack of signaling to stimulate NaCl reabsorption.
Inherited or acquired renal tubular disorders such as
Gitelman’s syndrome, Bartter’s syndrome, and related
medication-induced disorders,  such as from
aminoglycosides, cisplatin, diuretics, and foscarnet, are
often the diagnosis [70–72]. The evaluation of urine
divalent Mg2+ and Ca2+ excretion helps to localize the
exact tubular defect. A high urine Ca2+ and Mg2+
excretion is universally present in lesions of the loop
of Henle, whereas low urine Ca2+ and high Mg2+
excretion is invariably found in lesions of the distal
convoluted tubule [73–75]. A differential diagnosis of
Gitelman’s syndrome and different subtypes of Bartter’s
syndrome is shown in Table 3. It is important to
discriminate Gitelman’s syndrome from Bartter’s
syndrome because nonsteroidal anti-inflammatory drugs
are usually ineffective and not needed in treating patients
with Gitelman’s syndrome based on the relatively normal
urinary prostaglandin E
2
 excretion [76], unlike Bartter’s
syndrome with abnormally higher prostaglandin E
2
excretion, especially in antenatal type [77].
MANAGEMENT
The management of hypokalemia incorporates the
acuity of illness, magnitude of K+ deficit, K+
preparations, risks of therapy, and special associated
conditions.
Medical emergency
The major emergencies include cardiac arrhythmias and
respiratory failure. There are two notes of caution when
treating patients with profound hypokalemia in a
medical emergency. First, the aim of therapy is to get
Table 3. Differential diagnosis of Gitelman’s syndrome (GS) or Bartter’s syndrome (BS)-like inherited renal electrolyte disorders
GS aBS/HPS cBS BSND ADH
OMIM 263800 241200 602023 602522 601189
602023 600359
Inheritance AR AR AR AR AD
AR
Gene locus 16q 15q15-21 1p36 1p31 3q13.3-21
1p36 11q24
Gene SLC12A3 SLC12A1 CLCNKB BSND CASR
CLCNKB KCNJ1
Protein NCC Na+-K+-2Cl– CLC-Kb Barttin CASR
CLC-Kb ROMK
Clinical
Age at onset Variable Neonatal Variable Neonatal Infancy
Nephrocalcinosis No Yes Rare No Yes
Renal stones No Yes or no No No Yes
Laboratory
Blood pH B B B B B
Plasma K+ ? to ?? ? to ?? ? to ?? ?? ?
Plasma Mg2+ ? N or ? N or ? N ?
Plasma Ca2+ N N N N ?
Urine Mg2+ B N or B N or B N B
Urine Ca2+ ? BB Variable N or B BtoBB
OMIM = online Mendelian Inheritance in Man; aBS/HPS = antenatal Bartter’s syndrome/hyperprostaglandin E syndrome; cBS = classic
Bartter’s syndrome; BSND = antenatal Bartter’s syndrome with sensorineural deafness; ADH = autosomal dominant hypoparathyroidism;
AR = autosomal recessive; AD = autosomal dominant; CASR = calcium sensing receptor.
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the patient out of danger, not to immediately correct
the entire K+ deficit. Enough K+ must be given to raise
the plasma K+ quickly to a safe range (~3.0 mmol/L)
and the total body K+ deficit should then be replaced
more slowly [78]. Since large doses and high
concentrations of K+ might be needed, a central venous
catheter and cardiac monitor are essential for aggressive
treatment. Second, the infusion should not contain
glucose or HCO
3
– because this might aggravate the
degree of hypokalemia by increasing redistribution of
K+ from ECF into ICF space [79].
Magnitude of K+ deficit
Balance studies in K+-deprived normal subjects show
that when plasma K+ concentration decreases from 4
to 3 mmol/L, there is a mean K+ deficit of 350 mmol. A
further reduction in plasma K+ concentration from 3 to
2 mmol/L is associated with an additional 400 mmol
K+ deficit [13]. Given the degree of K+ loss, an estimated
amount of K+ supplement should be provided. The oral
route is preferred if bowel sounds are present. When a
peripheral intravenous route is used, the K+
concentration should not be > 40 mmol/L. The rate of
K+ administration should not be > 60 mmol/hr in all
but emergency settings. However, one must know that
there is no useful quantitative relationship between
plasma K+ and total body K+ deficit because there may
also be shift of K+ into cells such as in the presence of
coexisting volume depletion, metabolic alkalosis, and
increased `-adrenergic activity.
K+ preparations
Three kinds of K+ salts are available to replace body
K+ deficit: KCl, KHCO
3
 (K+ citrate or organic anion),
and K+ phosphate. KCl is needed in hypokalemic
patients with K+ deficit and hypochloremic metabolic
alkalosis, whereas KHCO
3
 or K+ citrate is preferred in
patients with K+ deficit and hyperchloremic metabolic
acidosis. KHCO
3
 or K+ citrate also has the significant
effect of reducing calcium excretion in patients with
metabolic acidosis. Because the administration of
HCO
3
– may lead to a shift of K+ into cells, KCl should
be given initially and alkali should be withheld unless
there are ongoing and large losses of HCO
3
–. K+
phosphate may be needed when there is concomitant
deficit of K+ and phosphate such as in the condition of
rapid anabolism, little oral intake, gastrointestinal
disorders, and preexisting cellular K+ phosphate loss
(e.g. diabetic or alcoholic ketoacidosis) [80].
Risks of therapy
In hypokalemic patients with acute increased shift K+
into cells, body K+ stores are normal. Aggressive KCl
therapy may be associated with a potential risk of
rebound hyperkalemia, due to K+ rapidly released from
cells when the K+ shift resolves [38,44,45]. With
prolonged hypokalemia, the CCD may become
temporarily hyporesponsive to the kaliuretic effect of
aldosterone [81]. Hyperkalemia may develop,
especially when K+ supplementation is given with K+-
sparing diuretics and if other conditions compromising
K+ excretion are present. These conditions include renal
failure, diabetes mellitus and the simultaneous use of
ACEIs, AII receptor blockers, beta-blockers or
nonsteroidal anti-inflammatory drugs [82]. However,
a recent retrospective study reported that total parenteral
nutrition as a source of K+, magnesium supplementation
which may reduce kaliuresis, and hematologic
malignancy causing cell lysis contribute to subsequent
hyperkalemia in one of every six patients with
hypokalemia [83].
Special associated settings
HPP due to transcellular shift of K+: In patients with
HPP, acute intravenous or oral KCl administration can
hasten recovery and prevent cardiac arrhythmia and
respiratory arrest. However, caution must be exercised
because KCl therapy is associated with the development
of rebound hyperkalemia on recovery. One interesting
but still less-appreciated finding is a further fall in
plasma K+ concentration in some patients with TPP
during KCl therapy. This paradoxical hypokalemia may
t r igger  phys ic ians  to  admin i s te r  more  K+
supplementation to correct the hypokalemia, leading
to marked rebound hyperkalemia. From retrospective
and case-controlled studies, rebound hyperkalemia
(> 5.0 mmol/L) has been reported to occur in close to
30–70% of patients with TPP if > 90 mmol KCl was
given within 24 hours or at a rate of 10 mmol/hr [84,
85]. We suggest that KCl supplementation be kept low
(< 10 mmol/hr) unless there are cardiopulmonary
complications. An alternative therapeutic option in TPP
is high-dose nonselective beta-blockers to suppress
adrenergic activity and inhibit insulin secretion, based
on the implication of hyperadrenergic activity and
hyperinsulinemia in the pathogenesis of TPP [86,87].
Nonselective beta-blockers may not only reverse an
acute episode of TPP without the development of
rebound hyperkalemia but also prevent or ameliorate
future paralytic attacks [88].
Associated with chronic hyponatremia: K+ may be
important in cerebral recovery following hyponatremia
because the cellular uptake of K+ is a critical response
to increasing extracellular tonicity. Hypokalemia is a
paramount risk factor for osmotic demyelination
syndrome (ODS) following the correction of chronic
hyponatremia [89]. It has been reported that 89% of
patients who developed ODS presented with initial
hypokalemia and that their K+ level did not normalize
with serum Na+ correction [90]. Normalizing the
hypokalemia either before, or at least concomitant with
the plasma Na+ correction would be a prudent and
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logical approach. There are many benefits of KCl
supplementation over NaCl, including the reduction of
arrhythmia related to hypokalemia, the Na+ gain in the
ECF and volume expansion if K+ enters the cells, and
reduced risk of ODS during correction of chronic
hyponatremia [89]. Nevertheless, the administration of
desmopressin is warranted to prevent or reduce a larger
water diuresis with a rapid and unwanted rise in plasma
Na+ concentration if aggressive KCl or NaCl therapy
causes ECF volume expansion with the resultant
inhibition of ADH release [91].
Associated with volume depletion: Because volume
depletion can cause an increase in _-adrenergic activity
and reduce the extracellular K+ shift into cells, plasma
K+ concentration is often misleadingly high [92]. When
volume status is restored in parallel with a reduction in
_-adrenergic activity, there will be a further fall in
plasma K+ concentration, leading to a paradoxical
worsening  of  hypokalemia  even  wi th  KCl
supplementation, similar to that found during K+
supplementation in the acute phase of HPP.
Associa ted  wi th  magnes ium defic iency:
Hypokalemia is frequently associated with magnesium
deficiency. It is estimated that > 50% of clinically
significant hypokalemia has concomitant magnesium
deficiency. Concomitant magnesium deficiency
exacerbates hypokalemia and renders it refractory to
treatment with K+ supplementation [93]. Micropuncture
studies have shown that magnesium decreases distal
K+ secretion [94]. In patch clamp studies, a decrease in
intracellular magnesium caused by magnesium
deficiency may release the magnesium-mediated
inhibition of ROMK channels and thus increase K+
secretion [95]. However, an increased Na+ delivery to
CCD or elevated aldosterone may be required for
aggravating K+ wasting in magnesium deficiency due
to the fact that magnesium deficiency alone does not
necessarily cause hypokalemia [96]. Correction of
magnesium deficiency may help in the correction of
hypokalemia and prevention of cardiac arrhythmia [97].
Associated with severe metabolic acidosis: Because
inorganic rather than organic acidosis causes the efflux
of intracellular K+ in exchange with extracellular H+
and thus raises plasma K+ concentration, the degree of
K+ deficit is underestimated in hypokalemic patients
with severe hyperchloremic metabolic acidosis [98].
One may be misled to correct the plasma HCO
3
– first
because the low HCO
3
– concentration appears more
dramatic than the K+ concentration in this setting.
Actually, the risk of profound hypokalemia is much
greater than severe metabolic acidosis and should be
corrected first. In fact, there have been case reports of
catastrophic acute respiratory failure and ventricular
arrhythmia from exacerbation of hypokalemia as a
result of aggressive alkali therapy before K+
supplementation.
Hypokalemia associated with hereditary renal
tubular defects: A common clinical observation is that
hypokalemia is difficult to correct in patients with
hereditary renal tubular disorders such as Gitelman’s
syndrome or Bartter’s syndrome, even with large K+
supplements. Because of chronic hypokalemia, luminal
K+ channels in the CCD might be downregulated [99].
KCl supplements transiently raise the plasma K+
concentration, which may not only augment the
insertion of K+ channels into the luminal membrane of
the CCD but also exert a loop diuretic-like effect, thus
inducing a prompt kaliuresis [100]. While maintaining
in a subnormal plasma K+ concentration, to administer
KCl in multiple small doses instead of infrequent large
doses may be a better way to avoid raising the plasma
K+ concentration to the normal range for even transient
periods.
Associated with a low lean mass: Because cellular
K+ primarily resides in the skeletal muscle, total body
K+ depends upon the lean muscle mass. For the same
degree of hypokalemia, K+ supplementation should be
relatively less in patients with low lean mass. If the
same amount of K+ replacement is given to patients
with low lean mass as to those with normal/high lean
mass, iatrogenic hyperkalemia may develop.
CONCLUSION
Hypokalemia caused by a multitude of etiologies is
often associated with cardiovascular, neuromuscular,
renal and metabolic disturbances. It usually arises from
derangements of internal K+ shift or external K+ balance.
Apart from detailed history and careful physical
examination, the measurement of urine K+ excretion
rate by spot and/or 24-hour urine, and assessment of
blood acid-base status will help to discriminate the
causes of hypokalemia. The treatment of hypokalemia
involves weighing the degree and timing of
hypokalemia with clinical manifestations, underlying
causes, associated conditions and risks during therapy.
Prompt diagnosis with appropriate management of
hypokalemia avoids unnecessary examination and dire
complications related to hypokalemia.
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